Oxidized LDL cholesterol is a risk factor for heart disease.
Stratum Nutrition’s (St. Louis) chitin-glucan ingredient Artinia may lower oxidized LDL cholesterol in humans, according to a study published in the European Journal of Clinical Nutrition.
Oxidized LDL cholesterol is cholesterol that has been exposed to high levels of free radicals. Evidence suggests that this form of cholesterol can greatly increase one’s risk of atherosclerotic heart disease.
In a six-week human clinical trial, researchers (including Stratum personnel) assigned 130 human subjects to six weeks of supplementation with Artinia, Artinia and olive oil extract (potentially anti-inflammatory), or placebo. All subjects reported in with borderline or high LDL levels.
At the end of the study, daily Artinia supplementation was deemed effective at lowering oxidized LDL cholesterol over placebo-in a high dose (4.5 g) or a low dose (1.5 g)-but the effect was only significant with the low dose. Artinia didn’t significantly affect HDL cholesterol, triglyceride, insulin or glucose levels in subjects.
Stratum pharmacology manager and coauthor of the study Joseph L Evans, PhD, said the study findings complement previous work performed on animal models.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.